Growth inhibition by dehydrothyrsiferol - A non-Pgp modulator, derived from a marine red alga - In human breast cancer cell lines

International Journal of Oncology

Volumn 14, Issue 4, 1999, Pages 739-743

  Pec, Martina K ^a   Moser Thier, Karin ^a   Fernández, José J ^b   Souto, María L ^b   Kubista, Ernst ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Dehydrothyrsiferol; Hs578T; Human breast cancer cell lines; Human epidermoid cell lines; KB 8 5; KB3 1; Multidrug resistance; Novel marine anticancerous drug; P glycoprotein; Pgp mediated efflux; T47D; ZR 75 1

Indexed keywords

ANTINEOPLASTIC AGENT; DEHYDROTHYRSIFEROL; FLUORESCENT DYE; GLYCOPROTEIN P; PYRAN DERIVATIVE; RHODAMINE 123;

ALGA; ARTICLE; BIOLOGY; BREAST TUMOR; CELL CULTURE; CELL DIVISION; CELL STRAIN KB; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ALGAE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT DYES; HUMANS; KB CELLS; MARINE BIOLOGY; P-GLYCOPROTEINS; PYRANS; RHODAMINE 123; TUMOR CELLS, CULTURED;

EID: 0033111914     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.4.739     Document Type: Article

References (23)

1. Norte M, Fernández JJ, Souto ML, Gavín JA and García-Grávalos MD: Thyrsenols A and B, two unusual polyether squalene derivatives. Tetrahedron 53: 3173-3178, 1997.
2. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D and Pirker R: MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231-1237, 1996.
3. Pirker I, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H and Lechner K: MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708-712, 1991.
4. Wang CS, LaRue H, Fortin A, Gariepy G and Tetu B: MDR1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res Treat 45: 63-74, 1997.
5. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ and Fruehauf JP: Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398, 1998.
6. Lehnert M: Clinical multidrug resistance in cancer - a multi-factorial problem. Eur J Cancer 32A: 912-920, 1996.
7. Watanabe T, Tsuge H, Oh-Hara T, Naito M and Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34: 234-241, 1995.
8. Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S and Figg WD: Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J Clin Pharmacol 37: 123-128, 1997.
9. Ehrlich PH, Moustafa ZA, Archinal-Mattheis AE, Newman MJ, Bair KW and Cohen D: The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833. Anticancer Res 17: 129-134, 1997.
10. Van der Blick A and Borst P: Multidrug-resistance. Adv Cancer Res 52: 165-203, 1989.
11. Magae J, Matsubara H, Aotsuka N, Kurasawa K and Shearer GM: Interleukin-2 does overcome suppression of graft rejection by cyclosporin A: effect of cyclosporin A on T cell properties in vivo. Cell Immunol 173: 276-281, 1996.
12. Scheuer PJ: Some marine ecological phenomena: chemical basis and biomedical potential. Science 248: 173-177, 1990.
13. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR and Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992.
14. Chiba P, Ecker G, Schmid D, Drach J, Tell B, Goldenberg S and Gekeler V: Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol Pharmacol 49: 1122-1130, 1996.
15. Shen D, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, Pastan I and Gottesman MM: Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261: 7762-7770, 1986.
16. Berridge MV, Tan AS, McCoy KD and Wang R: The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. Biochemica 4: 15-18, 1996.
17. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DF, Abbot BJ, Mayo JG, Shoemaker RH and Boyd MR: Feasability of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1988.
18. Whelan RDH and Hill BT: Differential expression of steroid receptors, hsp27, and pS2 in a serie of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation. Breast Cancer Res Treat 26: 23-39, 1993.
19. Minderman H, Vanhoefer U, Toth K, Yin MB, Minderman MD, Wrzosek C, Slovak ML and Rustum YM: DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 25: 14-20, 1996.
20. Lee I-S, Shamon LA, Chai H-B, Chagwedera TE, Besterman JM, Farnsworth NR, Cordell GA, Pezzuto JM and Kinghorn AD: Cell-cycle specific cytotoxicity mediated by rearranged entkaurene diterpenoids isolated from Parinari curatellifolia. Chem Biol Interact 99: 193-204, 1996.
21. Pec MK, Hellan M, Moser-Thier K, Fernández JJ, Souto ML and Kubista E: Inhibitory effects of a novel marine terpenoid on sensitive and multidrug resistant KB cell lines. Anticancer Res 18: 3027-3032, 1998.
22. De Jonge MJ, Sparreboom A and Verweij J: The development of combination therapy involving camptothecines: a review of preclinical and early clinical studies. Cancer Treat Rev 24: 205-220, 1998.
23. Distefano M, Scambia G, Ferlini C, Gaggini C, De Vincenzo R, Riva A, Bombardelli E, Ojima I, Fattorossi A, Panici PB and Mancuso S: Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer 72: 844-850, 1997.